by Marisa Wexler, MS | Dec 16, 2025 | Myeloma News
Johnson & Johnson (J&J) is asking the U.S. Food and Drug Administration (FDA) to approve a combination of two medications, Tecvayli (teclistamab) and Darzalex Faspro (daratumumab and hyaluronidase-fihj), for people with relapsed or refractory, or...
by Mark Leiser | Dec 15, 2025 | Uncategorized
ORLANDO — An in vivo chimeric antigen receptor T-cell therapy administered without lymphodepletion exhibited activity among patients with advanced multiple myeloma, according to findings presented at ASH Annual Meeting and Exposition.The first four patients treated...
by Andrea Lobo | Dec 15, 2025 | Myeloma News
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to SENTI-202, Senti Biosciences‘ experimental cell therapy being developed for adults with hard-to-treat blood cancers, including acute myeloid leukemia...
by MM360 Staff | Dec 15, 2025 | Publications
Curr Res Transl Med. 2025 Dec 2;74(1):103559. doi: 10.1016/j.retram.2025.103559. Online ahead of print. ABSTRACT BACKGROUND: Treatment of transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM) remains challenging due to age, frailty, and comorbidities....
by MM360 Staff | Dec 13, 2025 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
